These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29501579)

  • 1. Chondroitin sulfate protects vascular endothelial cells from toxicities of extracellular histones.
    Nagano F; Mizuno T; Mizumoto S; Yoshioka K; Takahashi K; Tsuboi N; Maruyama S; Yamada S; Nagamatsu T
    Eur J Pharmacol; 2018 May; 826():48-55. PubMed ID: 29501579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications.
    Fonseca RJ; Santos GR; Mourão PA
    Thromb Haemost; 2009 Nov; 102(5):829-36. PubMed ID: 19888516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides.
    Fonseca RJ; Oliveira SN; Pomin VH; Mecawi AS; Araujo IG; Mourão PA
    Thromb Haemost; 2010 May; 103(5):994-1004. PubMed ID: 20352164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 6. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis.
    Kalaska B; Sokolowska E; Kaminski K; Szczubialka K; Kramkowski K; Mogielnicki A; Nowakowska M; Buczko W
    Eur J Pharmacol; 2012 Jul; 686(1-3):81-9. PubMed ID: 22579410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of vascular human endothelial and rat smooth muscle cell growth by a fucosylated chondroitin sulfate from echinoderm.
    Tapon-Bretaudière J; Drouet B; Matou S; Mourão PA; Bros A; Letourneur D; Fischer AM
    Thromb Haemost; 2000 Aug; 84(2):332-7. PubMed ID: 10959709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin.
    Gray A; Litinas E; Jeske W; Fareed J; Hoppensteadt D
    Clin Appl Thromb Hemost; 2012; 18(2):166-73. PubMed ID: 22311630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Functional Roles and the Potential as Drug Targets of Glycoproteins Regulating Complement and Coagulation Pathways].
    Mizuno T
    Yakugaku Zasshi; 2023; 143(9):707-712. PubMed ID: 37661436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-α inhibitor protein and its associated glycosaminoglycans protect against histone-induced injury.
    Chaaban H; Keshari RS; Silasi-Mansat R; Popescu NI; Mehta-D'Souza P; Lim YP; Lupu F
    Blood; 2015 Apr; 125(14):2286-96. PubMed ID: 25631771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models.
    Vaezzadeh N; Ni R; Kim PY; Weitz JI; Gross PL
    Thromb Haemost; 2014 Aug; 112(2):412-8. PubMed ID: 24696126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfractionated heparin inhibits histone-mediated coagulation activation and thrombosis in mice.
    Li L; Yu S; Fu S; Ma X; Li X
    Thromb Res; 2020 Sep; 193():122-129. PubMed ID: 32559568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.
    Takahashi H; Ebihara S; Okazaki T; Asada M; Sasaki H; Yamaya M
    Br J Pharmacol; 2005 Oct; 146(3):333-43. PubMed ID: 16041398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulants: to bleed or not to bleed, that is the question.
    Da Silva MS; Sobel M
    Semin Vasc Surg; 2002 Dec; 15(4):256-67. PubMed ID: 12478500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation.
    Nordling S; Hong J; Fromell K; Edin F; Brännström J; Larsson R; Nilsson B; Magnusson PU
    Thromb Haemost; 2015 Jun; 113(6):1312-22. PubMed ID: 25740465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin: Effects upon the Glycocalyx and Endothelial Cells.
    Spiess BD
    J Extra Corpor Technol; 2017 Sep; 49(3):192-197. PubMed ID: 28979043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of histones F1 and F2 alpha 1, chondroitin sulfate A and their complexes on platelet aggregation induced by ADP and arachidonic acid].
    Czaczkowska T; Kłoczko J; Bielawiec M
    Acta Haematol Pol; 1986; 17(1-2):22-6. PubMed ID: 3096061
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
    Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.